

Company announcement – No. 02 / 2019

Zealand Pharma announces registration of executive management and an update of the Articles of Association

Copenhagen, February 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that Adam Steensberg has been registered with the Danish Business Authority as Interim Chief Executive Officer.

As announced in Company Announcement no. 1/2019 on January 23, 2019, Adam Steensberg has been appointed interim CEO, effective March 1, 2019, while also maintaining his current responsibilities, until a permanent CEO has been appointed.

An update to Zealand’s Articles of Association entailed by the change in executive management has been registered today with the Danish Business Authority.

For further information, please contact:

Adam Steensberg, Interim Chief Executive Officer,
Executive Vice President and Chief Medical & Development Officer
Tel.: +45 50 60 36 01, e-mail: ast@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.